Caitlin G Allen, Kimberly S Foss, Yue Guan, Kandamurugu Manickam, Hadley Stevens Smith, Adam H Buchanan, Jessica Ezzell Hunter, Aaron J Goldenberg
{"title":"Programmatic Considerations for Population-based Genomic Screening Implementation: An Expert-Informed Framework.","authors":"Caitlin G Allen, Kimberly S Foss, Yue Guan, Kandamurugu Manickam, Hadley Stevens Smith, Adam H Buchanan, Jessica Ezzell Hunter, Aaron J Goldenberg","doi":"10.1159/phg/aenag011","DOIUrl":"https://doi.org/10.1159/phg/aenag011","url":null,"abstract":"<p><strong>Purpose: </strong>Population-based genomic screening (PGS) offers significant public health potential by identifying individuals at risk for clinically actionable genetic conditions. While existing frameworks guide gene selection based on clinical actionability, defining programmatic considerations, including ethical, economic, and equity-related factors, is necessary to support population-level implementation. This review aims to develop a set of programmatic considerations to guide PGS implementation decisions.</p><p><strong>Methods: </strong>Using a structured, three-step deliberative process aligned with development of the Clinical Genome Resource (ClinGen) PGS Actionability Framework, multidisciplinary experts in public health genomics, clinical genetics, genetic counseling, ethics, health economics, and implementation science identified and refined key programmatic domains relevant to PGS implementation.</p><p><strong>Results: </strong>Eight programmatic consideration domains were identified: (1) Program Evaluation, (2) Justice, (3) Feasibility, (4) Acceptability, (5) Respect for Autonomy, (6) Population-Level Costs, (7) Analytic Validity/Test Performance, and (8) Program Management. Each domain was defined and accompanied by guiding questions to support implementation planning, addressing critical gaps by incorporating population-level concerns such as equity, sustainability, and public trust.</p><p><strong>Conclusion: </strong>These programmatic considerations provide essential contextual guidance to support ethical and effective implementation of PGS programs. Used alongside gene-level actionability frameworks, they can inform how screening programs are designed, operationalized, and evaluated to better align genomic medicine with population health priorities.</p>","PeriodicalId":49650,"journal":{"name":"Public Health Genomics","volume":" ","pages":"1"},"PeriodicalIF":2.2,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149289613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Heather Ramey, Jazmine Gabriel, Ana Morales, Katrina Romagnoli, Marc S Williams
{"title":"Cardiologists' perspectives on sociocultural and structural factors shaping cardiovascular genetic testing.","authors":"Heather Ramey, Jazmine Gabriel, Ana Morales, Katrina Romagnoli, Marc S Williams","doi":"10.1159/phg/aenag006","DOIUrl":"10.1159/phg/aenag006","url":null,"abstract":"<p><strong>Introduction: </strong>Genetic testing is increasingly central to the diagnosis and management of cardiovascular genetic conditions. However, use and follow-through vary across patient populations. Examining clinician perspectives on sociocultural and structural factors influencing testing is important for understanding these differences and informing public health genomics research and implementation efforts.</p><p><strong>Methods: </strong>We conducted semi-structured interviews with 15 cardiologists from health systems across the United States who have integrated cardiogenetics in their practice. Interviews explored experiences diagnosing cardiovascular genetic conditions among patients from underrepresented backgrounds, as well as approaches to incorporating social and contextual information into care. Data were coded thematically and analyzed using a framework analysis guided by the Health Equity Implementation Framework and Social Determinants of Health domains.</p><p><strong>Results: </strong>Clinicians described multi-level factors shaping genetic testing practices, including patient-provider interactions, clinical workflows, health system infrastructure, and broader policy contexts. Key themes included challenges communicating complex genetic information across language and literacy differences; patient trust shaped by prior healthcare experiences; fragmented insurance coverage separating genetic testing from genetic counseling; and challenges interpreting variants of uncertain significance, particularly for populations underrepresented in genomic reference databases. Clinicians also described adaptive strategies-such as interdisciplinary collaboration, telehealth, and patient assistance programs-that supported testing in some settings but were often inconsistent or resource-dependent.</p><p><strong>Conclusion: </strong>Among cardiologists using genetic testing, system-level and sociocultural factors shape the feasibility and downstream use of cardiovascular genetic testing. Findings highlight considerations for public health-informed genomic infrastructure that accounts for social context, supports communication, and reduces reliance on individual clinician workarounds, with implications for clinical decision support and related public health genomics initiatives.</p>","PeriodicalId":49650,"journal":{"name":"Public Health Genomics","volume":" ","pages":"1"},"PeriodicalIF":2.2,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149289706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Integration of Genomics into Public Health Practice: Work in Progress!","authors":"Muin J Khoury, Debra Duquette","doi":"10.1159/phg/aenag010","DOIUrl":"https://doi.org/10.1159/phg/aenag010","url":null,"abstract":"","PeriodicalId":49650,"journal":{"name":"Public Health Genomics","volume":" ","pages":"1"},"PeriodicalIF":2.2,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149247305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hui-Yi Lin, Carol Boxtha, Samaa El-Kolalli, Harun Mazumder, Justin Denis, Ashley O Apos Neil, Rania Abdulla, Teron Ricketts, Gustavo Alayon-Rosario, Jaime Matta, Hyun Park, Ratna Chakrabarti, Carmen Ortiz Sanchez, Stephanie Schmit, Jane Figueiredo, Shannon M Christy, Susan Vadaparampil, Kosj Yamoah, Clement K Gwede, Jong Yun Park
{"title":"Assessment of prostate cancer polygenic risk score in a community-based pilot study.","authors":"Hui-Yi Lin, Carol Boxtha, Samaa El-Kolalli, Harun Mazumder, Justin Denis, Ashley O Apos Neil, Rania Abdulla, Teron Ricketts, Gustavo Alayon-Rosario, Jaime Matta, Hyun Park, Ratna Chakrabarti, Carmen Ortiz Sanchez, Stephanie Schmit, Jane Figueiredo, Shannon M Christy, Susan Vadaparampil, Kosj Yamoah, Clement K Gwede, Jong Yun Park","doi":"10.1159/phg/aenag008","DOIUrl":"https://doi.org/10.1159/phg/aenag008","url":null,"abstract":"<p><strong>Background: </strong>Currently, prostate-specific antigen (PSA) testing remains the most important tool for prostate cancer (PCa) screening, yet it does not fully inform on personal risk level. Therefore, we collected information on screening behavior, family history, and polygenic risk score (PRS) from unaffected men to assess the association among PCa screening behavior, family history, and PRS.</p><p><strong>Methods: </strong>We collected past screening behavior, family history, and self-estimated risk information using a structured questionnaire, and saliva samples to generate PRS. Genotyping was conducted using the Illumina Oncoarray assay using saliva DNA. We investigated relationships among PCa screening behavior, family history, and PRS.</p><p><strong>Results: </strong>PRS information was generated from 76 unaffected men recruited from various community settings. Among 53 African American (AA) men, 13/53 (24.5%) were in the low-risk category (<30 percentile), and 17/53 (32%) were in the high-risk category (>70 percentile). In comparison, 21/23 (91%) of European American (EA) participants were in the low-risk category, and none of EA participants were in the high-risk category. AA men had a significantly higher PRS for PCa than EAs (p<0.001). Three variables (i.e., age, family history, and PRS) were significantly associated with prior PCa screening behaviors.</p><p><strong>Discussion: </strong>This study suggested differential genetic risk levels between racial groups. Men with a high risk of PCa could benefit from informed discussions around the risks and benefits of available options for PCa screening, especially among AA men. PRS information may assist AA men and clinicians in shared and informed decision-making discussions for routine PSA screening.</p>","PeriodicalId":49650,"journal":{"name":"Public Health Genomics","volume":" ","pages":"1"},"PeriodicalIF":2.2,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149225414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Muin J Khoury, Debra Duquette, Sonja A Rasmussen, Michael F Murray
{"title":"The Need for National Public Health Leadership in Planning for DNA-based Population Screening Across the Lifespan.","authors":"Muin J Khoury, Debra Duquette, Sonja A Rasmussen, Michael F Murray","doi":"10.1159/phg/aenag009","DOIUrl":"https://doi.org/10.1159/phg/aenag009","url":null,"abstract":"","PeriodicalId":49650,"journal":{"name":"Public Health Genomics","volume":" ","pages":"1"},"PeriodicalIF":2.2,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149208327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alexandra Blanco, Lisa Dellefave-Castillo, Megan Crowley-Matoka, Anya Prince, Debra Duquette, Sara Cherny
{"title":"\"I Don't Think It Is Fair…There Should be a Solution to Every Problem\": Experiences of Individuals with Sudden Arrhythmia Death Syndromes Who Attempt to Obtain Life Insurance.","authors":"Alexandra Blanco, Lisa Dellefave-Castillo, Megan Crowley-Matoka, Anya Prince, Debra Duquette, Sara Cherny","doi":"10.1159/phg/aenag007","DOIUrl":"https://doi.org/10.1159/phg/aenag007","url":null,"abstract":"<p><p>Sudden Arrhythmia Death Syndromes are a group of heritable genetic conditions that confer risk of sudden cardiac arrest or sudden cardiac death (SCA/SCD) in young, seemingly healthy individuals. Appropriate diagnosis of an SCA/SCD condition allows for guided management and prevents future sudden cardiac arrest and/or death from occurring. However, identification of a genetic predisposition can affect future insurance applications. While the United States' 2008 Genetic Information Non-discrimination Act (GINA) provides protection against genetic discrimination in employment and health insurance, it does not protect against the use of genetic information with regards to life insurance. This study aimed to expand the current understanding of life insurance experiences in the hereditary SCA/SCD community, gather strategies for individuals who wish to attain life insurance, and facilitate the development of life insurance specific patient and provider resources. Participants were recruited through The Sudden Arrhythmia Death Syndromes (SADS) Foundation. Semi-structured interviews were completed with 15 participants who have or are at-risk for SCA/SCD. Thematic analysis captured three themes: Emotional Outlook and Impact, Navigating the System, and Pay It Forward. Our participants with or at-risk for SCA/SCD expressed interest in attaining life insurance coverage that meets their individual needs and invested a meaningful amount of time and effort into their attempts. Most were unsuccessful. They perceived a lack of understanding regarding heritable SCA/SCD conditions by insurance professionals and felt their denials were unfairly attributed to their SCA/SCD diagnosis. Participants shared numerous suggestions for improved approaches to life insurance attainment and educational opportunities.</p>","PeriodicalId":49650,"journal":{"name":"Public Health Genomics","volume":" ","pages":"1"},"PeriodicalIF":2.2,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149197254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kristen L Kucera, Robert P Agans, Paul A Robbins, Yingwei Yang, Mary Anne McDonald, Paul H Haagen, Mina Silberberg, Lorrie Schmid, Deborah L Marean, Charmaine D M Royal
{"title":"Implementation of the National Collegiate Athletic Association Sickle Cell Trait Screening Policy: Methods and Staff and Athlete Perspectives.","authors":"Kristen L Kucera, Robert P Agans, Paul A Robbins, Yingwei Yang, Mary Anne McDonald, Paul H Haagen, Mina Silberberg, Lorrie Schmid, Deborah L Marean, Charmaine D M Royal","doi":"10.1159/000550672","DOIUrl":"10.1159/000550672","url":null,"abstract":"<p><strong>Introduction: </strong>This paper describes methods for a national study evaluating the implementation of the National Collegiate Athletic Association's (NCAA) policy on sickle cell trait (SCT) screening of athletes and describes attitudes toward the screening.</p><p><strong>Methods: </strong>In Fall 2020, 343 Division I schools, 302 Division II schools, and 426 Division III schools were invited to participate in this national survey.</p><p><strong>Results: </strong>Across 123 participating schools, a total of 168 sport medicine administrators (121 head athletic trainers and 47 team physicians), 268 athletic staff (128 staff athletic trainers and 140 coaches), and 1,424 athletes from basketball, football, soccer, lacrosse, track and field completed the survey. While the vast majority of respondents agreed/strongly agreed with the screening policy, there was varying support for how the policy was implemented including prioritizing SCT screening versus screening for other conditions (40-50% agreed/strongly agreed), focusing on sports with higher risk of overexertion versus universal screening (50-75% agreed/strongly agreed), and focusing on racial and ethnic groups where SCT is more prevalent (25-40% agreed/strongly agreed). Perspectives varied by NCAA division and race. Higher SCT knowledge scores were associated with believing that screening all athletes for SCT is important.</p><p><strong>Conclusions: </strong>Discussion of these findings provides important context for assessing how genetic screening requirements are implemented within collegiate athletics and more broadly.</p>","PeriodicalId":49650,"journal":{"name":"Public Health Genomics","volume":" ","pages":"94-108"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146214158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Single Nucleotide Polymorphisms in Orexin-1 and BDNF Receptor Genes are Associated with Increased Risk of Developing Postpartum Depression among Women with Gestational Diabetes Mellitus.","authors":"Pasha Ghazal, Shanza Tariq, Tehniyat Munshi","doi":"10.1159/000550243","DOIUrl":"10.1159/000550243","url":null,"abstract":"<p><strong>Introduction: </strong>Global studies have shown a bidirectional association of gestational diabetes mellitus (GDM) with postpartum depression (PPD). Despite high GDM prevalence in Pakistan (3.3%-17.8%), no prior studies have explored its link with PPD. In this study, association between GDM and risk of developing PPD was investigated and risk factors for PPD were identified using the gold-standard Edinburgh Postnatal Depression Scale (EPDS). Evidence suggests that PPD has strong genetic basis. The BDNF gene is a known candidate for PPD pathogenesis, while the orexin system is linked to arousal, energy metabolism, with emerging role in neuropsychiatric disorders. This study is the first study to explore association of orexin SNP ORX1 10914456 with PPD together with the BDNF SNP rs6265 (Val/Met66), among participants with and without GDM diagnosis.</p><p><strong>Methods: </strong>Among 1,000 women approached in hospitals of Islamabad, Rawalpindi, 800 met inclusion criteria (400 GDM, 400 non-GDM controls) and were genotyped for BDNF and orexin SNPs. Participants completed the EPDS 1 week postpartum.</p><p><strong>Results: </strong>Using a cutoff of ≥13, 84.9% of GDM patients and 18% of non-GDM controls scored ≥13 on EPDS (χ2 = 78.337, p < 0.00001). Multivariate logistic regression revealed GDM diagnosis, BMI >25, fasting plasma glucose >126 mg/dL, 31-39-week gestation, <12 years of education, and urban locality as significant risk factors for PPD. GDM diagnosis increased odds of PPD by 2.5-fold (OR = 2.5, 95% CI: 21.48-4.31, p < 0.0001). The orexin SNP Orx1 10914456, CC genotype and BDNF SNP rs6265, AA genotype increased the odds of having higher EPDS scores in GDM patients by 3.11 (OR = 3.11, 95% CI: 1.29-7.47, p < 0.001) and 3.3 (OR = 3.3, 95% CI: 1.31-8.13, p = 0.04, p < 0.05), respectively, in comparison to other genotypic variants.</p><p><strong>Conclusion: </strong>Our study supports orexin and BDNF system-targeted therapies for PPD.</p>","PeriodicalId":49650,"journal":{"name":"Public Health Genomics","volume":" ","pages":"39-54"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13008399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147318742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Saskia G Smits, Annelotte J Duintjer, Hermine A van Duyvenvoorde, Wendy Rodenburg, Mirjam van der Burg, Lidewij Henneman, Maartje Blom
{"title":"Key Outcomes from a Stakeholder Workshop on Genomic Newborn Screening: Recommended Next Steps for the Integration of Genomics into Public Health Programs.","authors":"Saskia G Smits, Annelotte J Duintjer, Hermine A van Duyvenvoorde, Wendy Rodenburg, Mirjam van der Burg, Lidewij Henneman, Maartje Blom","doi":"10.1159/000553190","DOIUrl":"10.1159/000553190","url":null,"abstract":"<p><strong>Introduction: </strong>Technical advances and decreasing costs of next-generation sequencing have generated global interest in its potential for newborn screening (NBS). Genomic NBS (gNBS) enables the expansion of detectable conditions as a first-tier test and can improve screening accuracy as a second-tier test. A shared vision among all involved stakeholders is essential to guide the next steps for gNBS in public health programs.</p><p><strong>Methods: </strong>A Dutch stakeholder workshop on gNBS was organized and attended by 56 participants from different fields, including clinical care, genetics, research, and NBS. The workshop aimed to inform about developments, identify challenges, foster connections, and build a shared vision. Based on the workshop outcomes, recommended next steps were formulated to support policy and practice decision-making for the integration of genomics into NBS.</p><p><strong>Results: </strong>Six key themes were identified from the workshop data: (1) expansion of the scope of NBS with genomics, (2) clinical aspects, (3) technical and workflow feasibility, (4) data storage and privacy issues, (5) information provision and consent, and (6) stakeholder roles and responsibilities. Participants highlighted challenges for gNBS, including reaching consensus on scope definition, systematic gene selection, standards for variant reporting, the large data volume, the complexity of information provision, and the current representation of stakeholders in NBS.</p><p><strong>Conclusion: </strong>The recommended next steps, derived from stakeholders' perceived challenges and considerations, reflect the complex and interconnected nature of integrating genomics into NBS, emphasizing the importance of alignment and coordination across disciplines. Translating these recommendations into public health NBS practice requires strong stakeholder engagement and enhanced multidisciplinary collaboration.</p>","PeriodicalId":49650,"journal":{"name":"Public Health Genomics","volume":" ","pages":"218-231"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13461120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148340826","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jeffery Osei, Sai Sripad Kodukula, Baffour Otchere, Om Raval, Webster Donaldy, Abhilash Suresh, Shoshana H Bardach, Jennifer Farnell, Ann Dodge, Diane MacDougall, Katherine Wilemon, Alexander C Razavi, Yan V Sun, Muin J Khoury, Laurence S Sperling
{"title":"Opportunities and Challenges in Translating Genomics into Population Health Impact: Lessons from Familial Hypercholesterolemia.","authors":"Jeffery Osei, Sai Sripad Kodukula, Baffour Otchere, Om Raval, Webster Donaldy, Abhilash Suresh, Shoshana H Bardach, Jennifer Farnell, Ann Dodge, Diane MacDougall, Katherine Wilemon, Alexander C Razavi, Yan V Sun, Muin J Khoury, Laurence S Sperling","doi":"10.1159/000553208","DOIUrl":"10.1159/000553208","url":null,"abstract":"<p><strong>Background: </strong>Familial hypercholesterolemia (FH) is a common, autosomal dominant genetic disorder characterized by lifelong elevations in low-density lipoprotein cholesterol and a markedly increased risk of premature atherosclerotic cardiovascular disease. Despite a well-defined genetic architecture, highly effective therapies, and strong evidence demonstrating the benefits of early identification and treatment, FH has historically remained underdiagnosed and undertreated worldwide. This persistent gap highlights broader challenges in translating genomic discovery into measurable population health impact.</p><p><strong>Summary: </strong>In this review, we examine how initiatives led by the Centers for Disease Control and Prevention, the Family Heart Foundation, and other stakeholders have advanced awareness, case identification, surveillance, evidence-based care, and implementation of genomic medicine in cardiovascular disease prevention. Using the framework of the Essential Public Health Services - assessment, policy development, and assurance/implementation - we evaluate progress achieved, identify implementation barriers, and highlight opportunities and recommendations to strengthen the population-level impact of FH detection, treatment, and prevention efforts.</p><p><strong>Key messages: </strong>The FH experience provides valuable lessons for other genomic conditions, demonstrating that achieving public health benefit requires more than scientific discovery. Greater investment in implementation science, a continued focus on health equity, and sustained systems-level engagement will be essential to translate genomic knowledge into durable and scalable improvements in population health.</p>","PeriodicalId":49650,"journal":{"name":"Public Health Genomics","volume":" ","pages":"269-277"},"PeriodicalIF":2.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13498316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148551281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}